E-Cigarettes Spark Evolution Of FDA’s Nicotine-Containing Medical Product Regulation
This article was originally published in The Tan Sheet
Executive Summary
FDA’s tobacco, drug and medical device centers are discussing “some sort of jurisdictional policy” to “determine how to evolve the regulation of therapeutic nicotine products,” including OTC drugs, says tobacco program head Mitch Zeller.
You may also be interested in...
E-cigarettes' Future Generates Questions, Not Their Efficacy For Smoking Cessation
FDA has made clear since e-cigarette sales emerged that they're not approved for labeling as products to help consumers stop using combustible tobacco. Agency also has acted on concerns about products' safety and appeal of flavored nicotine to minors. But likelihood of sales in US ending, not whether products help smokers quit, was discussed at FDLI conference.
Wider Options In FDA's NRT Clinical Trial Guidance, Approval Path Still Narrow
FDA's NRT clinical draft guidance is latest piece of its evolving strategy for making available more products to help smokers quit. But FDA maintains requirements that keep approval bar high and its separate draft guidance published in 2018 on nonclinical trials put NRT progress on hold, says Saul Shiffman, an OTC switch consultant with work includes multiple NRT proposals.
Turning Back Calendar Could Keep E-Cigarettes Available Without Approval
Exercising enforcement discretion concerning the grandfather date for e-cigarettes and other products covered in FDA’s proposed deeming rule would not be the agency’s first use of the enforcement tool in implementing Tobacco Control Act regulations.